Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor

Gregory De Crescenzo1, Cynthia S Hinck, Zhanyong Shu

  • 1Biotechnology Research Institute, National Research Council, Montreal, Que. Canada H4P2R2.

Insights

Transforming growth factor-beta (TGFbeta) isoforms have distinct roles. Researchers identified three specific amino acid residues in TGFbeta receptor type II (TbetaRII) that explain TGFbeta2

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Signaling

Background:

  • Transforming growth factor-beta (TGFbeta) isoforms 1, 2, and 3 are critical signaling molecules with distinct functions in development, tumor suppression, and wound healing.
  • These isoforms bind to TGFbeta type I and type II receptors (TbetaRI and TbetaRII) to transduce signals, but TGFbeta2 exhibits weaker binding to TbetaRII and relies on the co-receptor betaglycan.
  • Understanding the molecular basis for these differential binding affinities is crucial for elucidating TGFbeta signaling pathways.

Purpose of the Study:

  • To investigate the physicochemical basis for the differential binding affinities of TGFbeta isoforms to the TGFbeta receptor type II (TbetaRII).
  • To identify specific amino acid residues in TbetaRII that contribute to ligand binding affinity and equilibrium stability for TGFbeta isoforms.
  • To determine how specific amino acid substitutions in TGFbeta2 affect its binding affinity to TbetaRII.

Main Methods:

  • Generation of single amino acid variants of TbetaRII based on the crystal structure of the TbetaRII:TGFbeta3 complex.
  • Assays to measure TGFbeta isoform binding affinity to wild-type and variant TbetaRII.
  • Analysis of equilibrium stability of TbetaRII variants in complex with TGFbeta isoforms.

Main Results:

  • Specific TbetaRII residues (Ile53, Glu119, Asp32, Glu55, and Glu75) were identified as significant contributors to TGFbeta3 binding affinity.
  • These contacts account for the weaker binding affinity of TbetaRII to TGFbeta2, attributed to conservative substitutions at ligand residues Lys25, Ile92, and Lys94 in TGFbeta2 compared to TGFbeta1 and TGFbeta3.
  • A TGFbeta2 variant with residues mutated to match TGFbeta1 and TGFbeta3 exhibited comparable receptor binding affinities, confirming the role of these three residues.

Conclusions:

  • Three specific amino acid residues in TGFbeta2 are responsible for its lower binding affinity to TbetaRII compared to TGFbeta1 and TGFbeta3.
  • These identified residues and their interactions provide a molecular explanation for the differential binding of TGFbeta isoforms to their receptor.
  • All TGFbeta isoforms likely assemble the TGFbeta signaling receptor complex in a similar overall manner, despite variations in initial binding affinity.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high affinity and are together...
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...